DERM

Over the past six months, Journey Medical Corp.'s stock has been impacted by several events. In September 2026, the company's participation in investor conferences was followed by a -6.52% stock price change. On August 12, 2026, the announcement of strong Q2 2026 financial results, including 23% year-over-year total net revenue growth, a narrowed GAAP net loss, and positive EBITDA, led to a +3.42% stock price increase. Emrosi revenues reached $8.1 million in Q2 2026, driven by higher prescription volume and improved payer reimbursement, with prescriptions growing to 36,000. Following these results, B. Riley raised its price target on Journey Medical to $15 from $12, maintaining a 'Buy' rating. As of October 7, 2026, the stock closed at $5.95, having lost 21.2% over the past 12 months but gaining 13.77% over the past six months.